Use of empiric antimicrobial therapy in neutropenic fever

Grants

Funding Acknowledgements

Funding: These guidelines were developed independently through funding from Victorian Integrated Cancer Services. The Western and Central Melbourne Integrated Cancer Service (WCMICS), one of three metropolitan and five regional Integrated Cancer Services funded by the Victorian Department of Human Services to implement the Victorian Government's Cancer Services Framework across Victoria, administered this funding.Conflicts of interest: The following working group members are consultants or advisory committee members or receive honoraria, fees for service, or travel assistance (independent of research-related meetings) form; or have research or other associations with the organizations listed: Ian Davis - Novartis, Pfizer, GlaxoSmithKline, Schering-Plough; Andrew Grigg - Amgen, Gilead, Merck Sharp & Dohme, Novartis, Pfizer, Schering Plough, Sue Kirsa - Roche, Schering Plough, Amgen, Hospira, Alphapharm; Senthil Lingaratnam - Victorian Integrated Cancer Services; Orla Morrissey - Gilead, Merck Sharp & Dohme, Orphan, Pfizer, Schering Plough; William Renwick - Roche; Monica Slavin - Gilead, Merck Sharp & Dohme, Pfizer, Schering Plough; Brian Stein - Merck Serono; Constantine Tam - GSK, Roche; Karin Thursky - Gilead, Merck Sharp & Dohme, Pfizer, Schering Plough; Andrew Wei - Celgene, Hospira, Novartis.